Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Relay Therapeutics (RLAY) Interest & Investment Income (2020 - 2025)

Relay Therapeutics (RLAY) has disclosed Interest & Investment Income for 6 consecutive years, with $5.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Interest & Investment Income fell 36.37% to $5.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $27.0 million, a 22.19% decrease, with the full-year FY2025 number at $27.0 million, down 22.19% from a year prior.
  • Interest & Investment Income was $5.7 million for Q4 2025 at Relay Therapeutics, down from $6.4 million in the prior quarter.
  • In the past five years, Interest & Investment Income ranged from a high of $9.0 million in Q4 2024 to a low of $157000.0 in Q3 2021.
  • A 5-year average of $5.1 million and a median of $6.7 million in 2023 define the central range for Interest & Investment Income.
  • Peak YoY movement for Interest & Investment Income: plummeted 85.62% in 2021, then soared 1911.99% in 2022.
  • Relay Therapeutics' Interest & Investment Income stood at $267000.0 in 2021, then skyrocketed by 1911.99% to $5.4 million in 2022, then surged by 61.95% to $8.7 million in 2023, then rose by 3.15% to $9.0 million in 2024, then crashed by 36.37% to $5.7 million in 2025.
  • Per Business Quant, the three most recent readings for RLAY's Interest & Investment Income are $5.7 million (Q4 2025), $6.4 million (Q3 2025), and $7.1 million (Q2 2025).